AIM ImmunoTech is expected to report a Q2 2026 loss of $0.17 per share on minimal revenue of approximately $0.03 million, with its $0.28 stock price currently trading at a steep discount to the $9.50 average analyst target.
The primary focus for investors is the clinical trajectory of the company's lead drug, Ampligen, particularly progress in the DURIPANC Phase 2 trial for metastatic pancreatic cancer.
Recent milestones include the early completion of patient enrollment and dosing, which sets the stage for a pivotal Phase 3 study and top-line clinical benefit data expected in early 2027. Management’s ability to leverage its $9.9 million cash position to fund these late-stage oncology programs remains a critical narrative for the stock.